Emerging Issues in the Design of Clinical Trials for the
Development of new ARVs for HIV for Treatment Experienced
and Treatment Naïve Patient Populations

FCHR

September 30, 2010

PARTICIPANT LIST

Jeff Berry
AIDS Treatment Activists Coalition
Drug Development Committee

Julian Chick, PhD
Avexa

Susan Cox, PhD
Avexa Ltd
SVP Drug Development

Nikos Dedes
European AIDS Treatment Group

Steven G. Deeks, MD
University of California-San Francisco

Jerome Ernst, MD, MS
ACRIA

Wayne Greaves, MD
Merck

Richard Haubrich, MD
University of California San Diego

Robert (Bob) Huff
AIDS Treatment Activists Coalition

Filip Josephson, MD, PhD
Medical Products Agency/European Medicines
Association

Richard Klein, BS
U.S. Food and Drug Administration

Deborah Birnkrant, MD
U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Division of Antiviral Products

Eoin Coakley, MD
Monogram Biosciences

Judith Currier, MD, MSc
UCLA Care Center

Lynda Dee, JD
AIDS Action Baltimore, Inc.

Victor DeGruttola, ScD
Harvard School of Public Health
Department of Biostatistics

James Goodrich, MD, PhD
Viiv

Roy (Trip) Gulick, MD
Weill-Cornell Medical Center
Division of Infectious Diseases

Jayvant Heera, MD, MFPM
Pfizer Inc.

Sara Hughes, MSc, Cstat
ViiV Healthcare

Brian Kearney, PharmD
Gilead Sciences

Daniel Kuritzkes, MD
Brigham and Women's Hospital/ Harvard Medical School
Partners AIDS Research Center